Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ARZKN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
A114N NNAS-Mc-Val-Cit-PABC-MMAE
|
|||||
| Synonyms |
A114N NNAS-vcMMAE
Click to Show/Hide
|
|||||
| Organization |
Genzyme Corp.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8-4
|
|||||
| Antibody Name |
Anti-HER2 mAb A114N NNAS
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.